# Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)

> **NCT01969708** · PHASE3 · COMPLETED · sponsor: **The Emmes Company, LLC** · enrollment: 362 (actual)

## Conditions studied

- Central Retinal Vein Occlusion

## Interventions

- **DRUG:** aflibercept
- **DRUG:** bevacizumab

## Key facts

- **NCT ID:** NCT01969708
- **Lead sponsor:** The Emmes Company, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09
- **Primary completion:** 2016-11
- **Final completion:** 2021-03
- **Target enrollment:** 362 (ACTUAL)
- **Last updated:** 2021-06-22

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01969708

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01969708, "Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01969708. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*